Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

You may be eligible if

• Histologically confirmed\* solid tumor, including any of the following:
• * Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET)
• * Osteosarcoma
• * Rhabdomyosarcoma
• * Neuroblastoma
• * High-grade astrocytoma
• * Low-grade astrocytoma
• * Glioblastoma multiforme
• * Ependymoma
• * Hepatoblastoma
• * Germ cell tumors of any site
• * Rare tumors of interest, including any of the following:
• * Soft tissue sarcoma
• * Hepatocellular carcinoma
• * Childhood/adolescent colorectal carcinoma
• * Childhood/adolescent renal cell carcinoma
• * Childhood/adolescent adrenocortical carcinoma
• * Childhood/adolescent nasopharyngeal carcinoma
• Recurrent disease OR refractory to conventional therapy
• Measurable disease by clinical exam, CT scan, MRI, or positron emission tomography
• Performance status - Karnofsky 50-100% (for patients over age 10)
• Performance status - Lansky 50-100% (for patients age 10 and under)
• At least 8 weeks
• Absolute neutrophil count ≥ 1,000/mm\^3\*
• Platelet count ≥ 75,000/mm\^3\* (transfusion independent)
• Hemoglobin ≥ 8.0 g/dL\* (RBC transfusions allowed)
• Granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow metastases or extensive prior radiotherapy allowed provided the above hematological criteria are met
• Bilirubin ≤ 3 mg/dL
• Creatinine based on age as follows:
• * ≤ .8 mg/dL (for patients age 5 and under)
• * ≤ 1.0 mg/dL (for patients age 6 to 10)
• * ≤ 1.2 mg/dL (for patients age 11 to 15)
• * ≤1.5 mg/dL (for patients age 16 to 21)
• Creatinine clearance or radioisotope glomerular filtration rate \> 20 mL/min
• No uncontrolled seizure disorder
• No uncontrolled infection
• CNS toxicity ≤ grade 2
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Recovered from prior immunotherapy
• At least 7 days since prior anticancer biologic therapy
• More than 1 week since prior growth factors
• At least 6 months since prior allogeneic stem cell transplantation
• * No evidence of active graft-vs-host disease
• No concurrent immunomodulating agents
• Recovered from prior chemotherapy
• No prior oxaliplatin
• Prior carboplatin or cisplatin allowed
• More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
• No other concurrent anticancer chemotherapy
• Concurrent dexamethasone for CNS tumors allowed provided patient has been on a stable or decreasing dose for ≥ 1 week before study entry
• Recovered from prior radiotherapy
• At least 2 weeks since prior local palliative radiotherapy (small port)
• At least 6 months since prior craniospinal radiotherapy
• At least 6 months since prior radiotherapy to ≥ 50% of the pelvis
• At least 6 weeks since other prior substantial radiotherapy to the bone marrow
• Concurrent radiotherapy to localized painful lesions allowed provided ≥ 1 measurable lesion is not irradiated
• No other concurrent investigational agents
• No other concurrent anticancer agents